KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Revenue (2016 - 2026)

NovoCure's Revenue history spans 13 years, with the latest figure at $174.1 million for Q1 2026.

  • On a quarterly basis, Revenue rose 12.3% to $174.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $674.4 million, a 8.48% increase, with the full-year FY2025 number at $655.4 million, up 8.28% from a year prior.
  • Revenue hit $174.1 million in Q1 2026 for NovoCure, roughly flat from $174.4 million in the prior quarter.
  • Over the last five years, Revenue for NVCR hit a ceiling of $174.4 million in Q4 2025 and a floor of $122.2 million in Q1 2023.
  • Historically, Revenue has averaged $146.0 million across 5 years, with a median of $140.9 million in 2022.
  • Biggest five-year swings in Revenue: decreased 11.17% in 2023 and later rose 21.81% in 2024.
  • Tracing NVCR's Revenue over 5 years: stood at $128.4 million in 2022, then rose by 4.17% to $133.8 million in 2023, then grew by 20.54% to $161.3 million in 2024, then increased by 8.11% to $174.4 million in 2025, then dropped by 0.17% to $174.1 million in 2026.
  • Business Quant data shows Revenue for NVCR at $174.1 million in Q1 2026, $174.4 million in Q4 2025, and $167.2 million in Q3 2025.